Who
Michael Kauffman
Director
Company insider
Files Form 4 as: Director, Kyntra Bio; Director, Kezar Life Sciences; President of Development, Verastem; Director, Adicet Bio; Chief Executive Officer, Karyopharm Therapeutics; Director, Infinity Pharmaceuticals; Director, Zalicus; Chief Medical Officer, Onyx Pharmaceuticals.
In numbers
- Trades disclosed
- 363
- Buys
- 2
- Sells
- 69
- Bought
- $57K
- Sold
- $20.9M
- Companies
- 9
- Companies where not an officer
- 6
- First trade
- 6 Jan 2006
- Last trade
- 12 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 17 Jun 2026 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 Jun 2026filed 17 Jun 2026 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life SciencesBiotechnology | SEC FORM 4 Code U | —6,369 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —389 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,500 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —389 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —3,500 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —889 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —889 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —889 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —889 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciences | SEC FORM 4 Code U | —6,369 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
News
Verastem (NASDAQ:VSTM) Stock Price Target Raised at MizuhoVSTM · tickerreport.com · 16 Oct 2026Verastem (NASDAQ:VSTM) Shares Gap Up – Time to Buy?VSTM · tickerreport.com · 14 Oct 2026Verastem (NASDAQ:VSTM) Stock Falls 7% – Here's What HappenedVSTM · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Michael Kauffman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.